CJC-1295 with DAC vs without DAC: Complete Research Comparison
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog that has become one of the most widely studied peptides in endocrine research. It exists in two forms — with Drug Affinity Complex (DAC) and without DAC (also called Modified GRF 1-29 or Mod GRF). Understanding the differences between these two forms is crucial for researchers designing experimental protocols.
What is CJC-1295?
CJC-1295 is a 30-amino acid peptide analog of growth hormone-releasing hormone (GHRH). It was originally developed by ConjuChem Biotechnologies and designed to stimulate growth hormone (GH) secretion from the anterior pituitary gland. The peptide maintains the first 29 amino acids of native GHRH with modifications at positions 2, 8, 15, and 27 to improve stability against enzymatic degradation by dipeptidyl peptidase IV (DPP-IV).
CJC-1295 with DAC
What is DAC?
DAC (Drug Affinity Complex) is a lysine-linked maleimidopropionic acid modification that allows CJC-1295 to covalently bind to serum albumin after injection. This albumin binding dramatically extends the peptide’s biological half-life from minutes to approximately 6-8 days.
Key Characteristics
- Half-life: 6-8 days (due to albumin binding)
- GH elevation pattern: Sustained, continuous elevation
- Dosing frequency: Once or twice weekly in research protocols
- GH pulsatility: Blunted — creates a steady-state elevation rather than natural pulsatile release
- IGF-1 elevation: Significant and sustained increase over baseline
Research Findings
In clinical studies, CJC-1295 with DAC demonstrated dose-dependent increases in GH and IGF-1 levels, sustained GH elevation for 6+ days after single injection, 2-10x increase in mean GH concentrations, and significant IGF-1 elevation lasting up to 28 days.
CJC-1295 without DAC (Mod GRF 1-29)
Key Characteristics
- Half-life: ~30 minutes
- GH elevation pattern: Acute pulse followed by return to baseline
- Dosing frequency: 2-3 times daily in research protocols
- GH pulsatility: Preserved — mimics natural GH release pattern
- Synergy: Often combined with GHRPs (GHRP-6, GHRP-2, Ipamorelin) for amplified response
Side-by-Side Comparison
| Parameter | CJC-1295 with DAC | CJC-1295 without DAC |
|---|---|---|
| Half-Life | 6-8 days | ~30 minutes |
| Dosing Frequency | 1-2x per week | 2-3x per day |
| GH Release Pattern | Sustained elevation | Pulsatile (natural) |
| IGF-1 Impact | Prolonged elevation | Transient elevation |
| Albumin Binding | Yes (via DAC) | No |
| Common Pairing | Used alone | Combined with GHRPs |
| Research Convenience | Higher (less frequent dosing) | Lower (multiple daily doses) |
Which Form is Better for Research?
The choice depends on the research objective. CJC-1295 with DAC is preferred for studies requiring sustained GH/IGF-1 elevation, long-term metabolic research, and protocols where dosing frequency must be minimized. CJC-1295 without DAC is preferred for studies requiring physiological GH pulsatility, combinatorial protocols with GHRPs, and research on acute GH response dynamics.
Research-Grade CJC-1295 from Aarise Healthcare
Aarise Healthcare supplies both forms of CJC-1295 — with and without DAC — at ≥98% purity verified by HPLC. Each batch includes comprehensive Certificate of Analysis. Browse our peptide catalog or contact us for research supply inquiries.
Related Articles
- Research Peptides vs Research Steroids — Differences, Mechanisms & Applications
- AOD-9604 Peptide Research Guide — Mechanism, Studies & Applications
- Tirzepatide Research Compound — Mechanism, GLP-1/GIP Dual Agonism & Study Applications
- Semaglutide Research Compound — GLP-1 Agonist Mechanism, Applications & Purity Guide
Also from Aarise Group:
